conova deploys ADVA OLS solution for highly secure DCI connectivity
19.11.2019 11:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that conova communications is using its technology for secure, high-capacity transport between data centers. conova, one of Austria’s leading IT service providers, has deployed the ADVA FSP 3000 open line system (OLS) with ConnectGuard™ Optical encryption in response to booming demand from business customers for reliable and protected cloud services. The fully redundant infrastructure supports 100Gbit/s Carrier Ethernet as well as 32Gbit/s Gen 6 Fibre Channel, a key requirement for the most advanced enterprise storage services. Featuring ADVA ALM fiber assurance technology, the new DCI network also enables rapid repair times and improves performance. The solution was designed and implemented by ADVA’s Elite partner dacoso, a German IT service provider focusing on connectivity, cyber defense and virtual networking.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005076/en/
ADVA's technology takes conova's DCI network to new heights (Photo: Business Wire)
“In recent years, we’ve grown rapidly as our customers’ businesses have expanded. ADVA’s technology enables us to meet new levels of demand for high-security, high-availability cloud and storage services in a way that also supports further growth in the future. With the ability to transport the most advanced low-latency 32Gbit/s Fibre Channel services, our new network also empowers us to realize the full value of our state-of-the-art data centers,” said Stefan Kaltenbrunner, CSO, conova. “Our new fully redundant network is key to our mission of delivering the optimal IT infrastructure for every business. It helps us provide our customers with fast access to their mission-critical data around the clock as well as the peace of mind that comes from knowing that it’s safe and secure.”
conova’s new network is built on the ADVA FSP 3000 OLS, a high-performance packet-optical solution with low-power consumption and an extremely compact design. The infrastructure is protected by ConnectGuard™ Optical for network encryption at the lowest network layer. This is not only the most robust security method available, but it also maximizes throughput and ensures the lowest possible latency. The network is assured by the ADVA ALM fiber monitoring solution, which provides real-time information on fiber integrity for fast failure detection and short repair cycles. As the first platform on the market to achieve mainframe qualification for Gen 6 Fibre Channel transport, the ADVA FSP 3000 enables conova to make the leap to 32Gbit/s Fibre Channel and maximize the performance of flash-enhanced data storage in its facilities.
“When it comes to data center interconnect technology that offers agility, security and speed, our portfolio and our team are second to none. We’ve provided conova with a network optimized for the fastest, most reliable SAN connectivity. Now its team is free to tackle soaring data demand using flash storage and other latest-generation technologies,” commented Andreas Jelinek, senior director, sales, Eastern Europe, Russia and CIS, ADVA. “Today’s enterprise customers need their data to be constantly available but also expect it to be fully protected. With our simple and effective technology, conova’s customers can be assured that all data and control traffic is safe. What’s more, as our ConnectGuard™ Optical encryption technology adds just 100ns of latency, total security comes at virtually no cost to performance.”
“Together with ADVA, we’ve delivered the ideal DCI network for conova’s specific needs. It’s a future-proof solution that ensures excellent performance as well as robust protection of data integrity,” said Christian Cehovin, country manager, Austria, dacoso. “We’ve worked very closely with ADVA on this project to ensure there could be no room for error. Together we’ve built up a formidable reputation for designing and installing solutions that provide low-latency, high-capacity transport for business continuity and disaster recovery. conova’s solution is the product of ADVA’s world-class technology, the energy and passion of our team and a wealth of combined expertise. And, with our ongoing maintenance and support, it’s sure to provide value for conova’s customers for many years to come.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005076/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
